Palomino Laboratories (PALX) Liabilities and Shareholders Equity (2022 - 2025)

Palomino Laboratories (PALX) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $8.4 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 6006.17% year-over-year to $8.4 million; the trailing twelve-month figure through Dec 2025 stood at $16.8 million (up 11949.68% YoY), and the FY2025 full-year result was $8.4 million, up 6006.17% from the prior year.
• Liabilities and Shareholders Equity climbed to $8.4 million in Q4 2025, from $8.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $8.4 million in Q4 2025 to a low of $322.0 in Q2 2024.
• A 4-year average of $1.5 million and a median of $500.0 in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity dropped 24.0% in 2023 and soared 2581502.8% in 2025, its largest moves.
• Tracing PALX's Liabilities and Shareholders Equity over 4 years: stood at $500.0 in 2022, then retreated by 24.0% to $380.0 in 2023, then soared by 36248.68% to $138125.0 in 2024, then soared by 6006.17% to $8.4 million in 2025.
• Business Quant data shows PALX's Liabilities and Shareholders Equity at $8.4 million in Q4 2025, $8.3 million in Q3 2025, and $1887.0 in Q2 2025.